Kolon TissueGene (950160) saw its U.S. osteoarthritis cell and gene therapy 'TG-C' Phase 3 clinical trial results fall short of market expectations, recording lower limits for two consecutive days on the 21st and 22nd, closing at 30,050 won on the 22nd. The market is on high alert over whether a technical rebound will appear in the 23rd's trading session or selling pressure will continue.

As TG-C is considered Kolon TissueGene's core pipeline, disappointment over the clinical results directly led to a contraction in investor sentiment. Selling pressure continued down to the price limit, sharply expanding short-term volatility.

The company has clarified that it is proceeding with the remaining Phase 3 clinical studies as originally planned and will disclose additional data in the future. However, the prevailing view in the market is that it will take time for investor sentiment to recover before uncertainties surrounding the core pipeline are resolved.

On the 23rd, the possibility of a technical rebound driven by an influx of bargain-hunting buyers and whether the contraction in investor sentiment will persist emerged as key focal points. The biotech sector tends to experience significantly widening stock price fluctuations following clinical results announcements, making subsequent clinical schedules and related disclosures key variables that will dictate future share prices.

Experts advise that a cautious approach to investment decisions is necessary given the extreme price volatility. Opinions have been raised that investors should respond by comprehensively reviewing additional clinical data and business progress rather than focusing on short-term trends.

[※ This article is for reference in making investment decisions and does not recommend buying or selling any specific stock. The final responsibility for investments lies with the investor.]